These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 23149332)

  • 41. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Different patterns of vascular response between patients with or without diabetes mellitus after drug-eluting stent implantation: optical coherence tomographic analysis.
    Tanaka N; Terashima M; Rathore S; Itoh T; Habara M; Nasu K; Kimura M; Itoh T; Kinoshita Y; Ehara M; Tsuchikane E; Asakura K; Asakura Y; Katoh O; Suzuki T
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1074-9. PubMed ID: 20965467
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optical coherence tomographic observation of in-stent neoatherosclerosis in lesions with more than 50% neointimal area stenosis after second-generation drug-eluting stent implantation.
    Lee SY; Hur SH; Lee SG; Kim SW; Shin DH; Kim JS; Kim BK; Ko YG; Choi D; Jang Y; Hong MK
    Circ Cardiovasc Interv; 2015 Feb; 8(2):e001878. PubMed ID: 25613674
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: comparison with a drug eluting stent and a bare metal stent.
    Clever YP; Cremers B; Speck U; Dietz U; Böhm M; Scheller B
    Catheter Cardiovasc Interv; 2014 Aug; 84(2):323-31. PubMed ID: 23996969
    [TBL] [Abstract][Full Text] [Related]  

  • 46. First serial assessment at 6 months and 2 years of the second generation of absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study.
    Ormiston JA; Serruys PW; Onuma Y; van Geuns RJ; de Bruyne B; Dudek D; Thuesen L; Smits PC; Chevalier B; McClean D; Koolen J; Windecker S; Whitbourn R; Meredith I; Dorange C; Veldhof S; Hebert KM; Rapoza R; Garcia-Garcia HM
    Circ Cardiovasc Interv; 2012 Oct; 5(5):620-32. PubMed ID: 23048057
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Liberté stents in de novo native coronary artery lesions.
    Otake H; Honda Y; Courtney BK; Shimohama T; Ako J; Waseda K; Macours N; Rogers C; Popma JJ; Abizaid A; Ormiston JA; Spaulding C; Cohen SA; Fitzgerald PJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):146-54. PubMed ID: 21386089
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Impact of angiographic and intravascular ultrasound features on clinical outcome after sirolimus-eluting stent implantation for de-novo lesions in nondiabetic and type 2 diabetic patients.
    Du R; Zhang RY; Zhu ZB; Zhang Q; Hu J; Yang ZK; Yan ZJ; Lv AK; Ding FH; Zhang JS; Shen WF
    Coron Artery Dis; 2010 May; 21(3):175-81. PubMed ID: 20305549
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neointimal tissue component assessed by tissue characterization with 40 MHz intravascular ultrasound imaging: comparison of drug-eluting stents and bare-metal stents.
    Tsujita K; Takaoka N; Kaikita K; Hokimoto S; Horio E; Sato K; Mizobe M; Nakayama N; Kojima S; Tayama S; Sugiyama S; Nakamura S; Ogawa H
    Catheter Cardiovasc Interv; 2013 Dec; 82(7):1068-74. PubMed ID: 23460385
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study.
    Guagliumi G; Sirbu V; Bezerra H; Biondi-Zoccai G; Fiocca L; Musumeci G; Matiashvili A; Lortkipanidze N; Tahara S; Valsecchi O; Costa M
    JACC Cardiovasc Interv; 2010 Jun; 3(6):680-7. PubMed ID: 20630463
    [TBL] [Abstract][Full Text] [Related]  

  • 51. 3-year clinical follow-up of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions: the SPIRIT II trial (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions).
    Garg S; Serruys P; Onuma Y; Dorange C; Veldhof S; Miquel-Hébert K; Sudhir K; Boland J; Huber K; Garcia E; te Riele JA;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1190-8. PubMed ID: 20129545
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gender-based evaluation of the XIENCE V everolimus-eluting coronary stent system: clinical and angiographic results from the SPIRIT III randomized trial.
    Lansky AJ; Ng VG; Mutlu H; Cristea E; Guiran JB; Midei M; Newman W; Sanz M; Sood P; Doostzadeh J; Su X; White R; Cao S; Sudhir K; Stone GW
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):719-27. PubMed ID: 19530147
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Major determinants for the uncovered stent struts on optical coherence tomography after drug-eluting stent implantation.
    Kim BK; Kim JS; Oh C; Ko YG; Choi D; Jang Y; Hong MK
    Int J Cardiovasc Imaging; 2012 Apr; 28(4):705-14. PubMed ID: 21626042
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Randomized comparison of a polymer-free sirolimus-eluting stent versus a polymer-based paclitaxel-eluting stent in patients with diabetes mellitus: the LIPSIA Yukon trial.
    Desch S; Schloma D; Möbius-Winkler S; Erbs S; Gielen S; Linke A; Yu J; Lauer B; Kleinertz K; Dänschel W; Schuler G; Thiele H
    JACC Cardiovasc Interv; 2011 Apr; 4(4):452-9. PubMed ID: 21511226
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Serial intravascular ultrasound analysis of complex bifurcation coronary lesions treated with the Tryton Bifurcation Stent in conjunction with an everolimus-eluting stent: IUVANT (Intravascular Ultrasound Evaluation of Tryton Stent) study.
    Bartorelli AL; Trabattoni D; Almonacid A; Fabbiocchi F; Montorsi P; Galli S; Grancini L; Ravagnani P; Mintz GS; Kaplan AV; Popma JJ; Maehara A
    Catheter Cardiovasc Interv; 2015 Mar; 85(4):544-53. PubMed ID: 25115944
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimal stent-sizing with intravascular ultrasound contributes to complete neointimal coverage after sirolimus-eluting stent implantation assessed by angioscopy.
    Sera F; Awata M; Uematsu M; Kotani J; Nanto S; Nagata S
    JACC Cardiovasc Interv; 2009 Oct; 2(10):989-94. PubMed ID: 19850260
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparison of zotarolimus-eluting stents with sirolimus-eluting and paclitaxel-eluting stents: intimal hyperplasia and vascular changes assessed by volumetric intravascular ultrasound analysis.
    Kang SJ; Mintz GS; Park DW; Lee SW; Kim YH; Lee CW; Han KH; Kim JJ; Park SW; Park SJ
    Circ Cardiovasc Interv; 2011 Apr; 4(2):139-45. PubMed ID: 21364151
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Impact of polymer formulations on neointimal proliferation after zotarolimus-eluting stent with different polymers: insights from the RESOLUTE trial.
    Waseda K; Ako J; Yamasaki M; Koizumi T; Sakurai R; Hongo Y; Koo BK; Ormiston J; Worthley SG; Whitbourn RJ; Walters DL; Meredith IT; Fitzgerald PJ; Honda Y
    Circ Cardiovasc Interv; 2011 Jun; 4(3):248-55. PubMed ID: 21586691
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomized, controlled, multicenter trial to evaluate the safety and efficacy of zotarolimus- versus paclitaxel-eluting stents in de novo occlusive lesions in coronary arteries The ZoMaxx I trial.
    Chevalier B; Di Mario C; Neumann FJ; Ribichini F; Urban P; Popma JJ; Fitzgerald PJ; Cutlip DE; Williams DO; Ormiston J; Grube E; Whitbourn R; Schwartz LB;
    JACC Cardiovasc Interv; 2008 Oct; 1(5):524-32. PubMed ID: 19463354
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optical coherence tomography findings of very late stent thrombosis after drug-eluting stent implantation.
    Ko YG; Kim DM; Cho JM; Choi SY; Yoon JH; Kim JS; Kim BK; Choi D; Jang Y; Hong MK
    Int J Cardiovasc Imaging; 2012 Apr; 28(4):715-23. PubMed ID: 21656060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.